Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine

• Main Authors: Xiaolan Yong (Author), Jun Liu (Author), Ying Zeng (Author), Jing Nie (Author), Xuelian Cui (Author), Tao Wang (Author), Yilin Wang (Author), Yiyong Chen (Author), Wei Kang (Author), Zhonghua Yang (Author), Yan Liu (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

LYB001 is an innovative recombinant SARS-CoV-2 vaccine that displays a repetitive array of the spike glycoprotein's receptor-binding domain (RBD) on a virus-like particle (VLP) vector to boost the immune system, produced using Covalink plug-and-display protein binding technology. LYB001's...